B

Braidwell Portfolio holdings

AUM $2.7B Turnover 43.12%
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-5.73%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.16B
AUM Growth
+$104M
Cap. Flow
-$1.09B
Cap. Flow %
-34.59%
Top 10 Hldgs %
35.35%
Holding
97
New
14
Increased
28
Reduced
11
Closed
11
Avg Time Held
0.5 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.4 years

Top Buys

Rank Stock Value
1
BCYC icon
Bicycle Therapeutics
BCYC
+$29.5M
2
ETNB icon
89bio
ETNB
+$26.7M
3
IMCR icon
Immunocore
IMCR
+$26M
4
TMO icon
Thermo Fisher Scientific
TMO
+$25.8M
5
INSP icon
Inspire Medical Systems
INSP
+$25.3M

Top Sells

Rank Stock Value
1
DICE icon
DICE Therapeutics, Inc. Common Stock
DICE
+$47.8M
2
BIIB icon
Biogen
BIIB
+$34.7M
3
ALGN icon
Align Technology
ALGN
+$34.1M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$30.1M
5
GKOS icon
Glaukos
GKOS
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 51.8%
2 Miscellaneous 47.89%
3 Consumer Staples 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NBIX icon
1
Neurocrine Biosciences
NBIX
$13.8B
$109M 3.44%
968,024
+34,662
+4% +$3.65M
2023 Q1
2 quarters
PCVX icon
2
Vaxcyte
PCVX
$10.6B
$82.6M 2.61%
1,619,553
-102,800
-6% -$5.07M
2022 Q4
3 quarters
XENE icon
3
Xenon Pharmaceuticals
XENE
$3.28B
$71.9M 2.27%
2,103,396
+275,043
+15% +$10.3M
2022 Q4
3 quarters
BSX icon
4
Boston Scientific
BSX
$62.3B
$61.5M 1.94%
1,164,850
+447,800
+62% +$23.5M
2023 Q2
1 quarter
LEGN icon
5
Legend Biotech
LEGN
$3.7B
$59.1M 1.87%
879,564
+323,263
+58% +$22.5M
2022 Q4
3 quarters
IRTC icon
6
iRhythm Holdings
IRTC
$3.5B
$53.6M 1.69%
568,157
+89,600
+19% +$9.11M
2022 Q4
3 quarters
GKOS icon
7
Glaukos
GKOS
$9.9B
$52.4M 1.65%
695,792
-348,600
-33% -$26M
2022 Q4
3 quarters
IMCR icon
8
Immunocore
IMCR
$1.46B
$47.1M 1.49%
906,973
+438,946
+94% +$26M
2023 Q1
2 quarters
DAWN icon
9
DELISTED
Day One Biopharmaceuticals
DAWN
$45.6M 1.44%
3,715,573
+353,760
+11% +$4.61M
2022 Q4
3 quarters
NTRA icon
10
Natera
NTRA
$56.9B
$44.8M 1.42%
1,012,145
-140,706
-12% -$7.18M
2022 Q4
3 quarters
KROS icon
11
Keros Therapeutics
KROS
$219M
$43.3M 1.37%
1,357,309
+213,444
+19% +$7.97M
2023 Q2
1 quarter
DCPH icon
12
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$42.4M 1.34%
3,336,221
-310,198
-9% -$4.28M
2022 Q4
3 quarters
FNA icon
13
DELISTED
Paragon 28, Inc.
FNA
$42.2M 1.33%
3,361,824
+1,225,702
+57% +$18.5M
2023 Q1
2 quarters
MRVI icon
14
Maravai LifeSciences
MRVI
$976M
$39.7M 1.26%
3,974,857
+2,170,157
+120% +$23.8M
2023 Q2
1 quarter
TMO icon
15
Thermo Fisher Scientific
TMO
$249B
$38.3M 1.21%
75,749
+48,449
+177% +$25.8M
2023 Q2
1 quarter
ALGN icon
16
Align Technology
ALGN
$10.3B
$38.2M 1.21%
125,213
-98,817
-44% -$34.1M
2022 Q4
3 quarters
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$2.06B
$38M 1.2%
5,362,980
+2,571,100
+92% +$18.5M
2023 Q1
2 quarters
NVRO icon
18
DELISTED
NEVRO CORP.
NVRO
$34.1M 1.08%
1,776,368
– –
2022 Q4
3 quarters
KIDS icon
19
OrthoPediatrics
KIDS
$581M
$33.8M 1.07%
1,057,770
+296,562
+39% +$11.4M
2022 Q4
3 quarters
ISRG icon
20
Intuitive Surgical
ISRG
$148B
$33.6M 1.06%
114,920
-8,900
-7% -$2.78M
2022 Q4
3 quarters
VRDN icon
21
Viridian Therapeutics
VRDN
$2.08B
$26.6M 0.84%
1,735,182
+528,882
+44% +$10.1M
2023 Q2
1 quarter
ALEC icon
22
Alector
ALEC
$210M
$26.4M 0.83%
4,074,120
-57,195
-1% -$370K
2022 Q4
3 quarters
OM icon
23
Outset Medical
OM
$72.2M
$26.1M 0.83%
160,028
+62,670
+64% +$14.8M
2022 Q4
3 quarters
HROW icon
24
Harrow
HROW
$1.02B
$26M 0.82%
1,808,684
+356,146
+25% +$6.23M
2023 Q1
2 quarters
BCYC icon
25
Bicycle Therapeutics
BCYC
$246M
$25.9M 0.82%
+1,289,872
New +$29.5M
2023 Q3
0 quarters
1
2 3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q3 2023 Portfolio in Review

As of Q3 2023, Braidwell held 97 positions worth $3.16B, up 3.4% from $3.06B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Braidwell withdrew a net $1.09B in Q3 2023, closing 11 positions and reducing 11 holdings. Its most notable exit was DICE Therapeutics, Inc. Common Stock, an estimated $47.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 54% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Bicycle Therapeutics worth $25.9M.

  • Braidwell's largest Q3 2023 buy was Bicycle Therapeutics: 1,289,872 shares worth $25.9M.
  • Braidwell added most to Immunocore in Q3 2023, an estimated $26M increase.
  • Braidwell's biggest Q3 2023 reduction was Align Technology, cutting an estimated $34.1M.
  • Braidwell fully exited DICE Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $47.8M.
  • Braidwell's ten largest holdings make up 35% of its $3.16B portfolio in Q3 2023.
  • Braidwell opened 14 new positions and closed 11 in Q3 2023.
  • Braidwell's portfolio value rose 3.4% quarter-over-quarter to $3.16B.

Based on Braidwell's 13F filing for Q3 2023, filed 14 Nov 2023.